Calretinin expression as a risk biomarker for metastatic canine mammary carcinoma

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Malignant breast tumors are the most common tumors in humans and are associated with a poor prognosis. An accurate animal model of human mammary gland tumorigenesis is needed to test novel diagnosis and treatment strategies. Dogs represent a promising model since they develop such tumors spontaneously. In the present study, three immunomarkers, including calretinin, c-Kit (CD117) and placental alkaline phosphatase (Plap), were used and compared with each other, in relation to estrogen and progesterone receptors and HER2 (triple markers), with the intention of malignancy grading. Enhanced expression of calretinin and placental alkaline phosphatase, without immunoreaction to c-Kit in neoplastic cells, is related to high-grade malignancy. Out of 50 tumors, 31 were metastasized, 29 of which (93.5%) were moderately to strongly calretinin positive (P<0.05). However, the results for c-Kit-and Plap+ in metastatic tumors were not reproducible. It may be concluded that calretinin could be introduced as a determinant biomarker in the diagnosis of breast cancer metastasis.

Cite

CITATION STYLE

APA

Dezfoulian, O., Akbarein, H., Jamshidi, S., Golshahi, H., Lakooraj, H. M., & Haghighi, L. (2020). Calretinin expression as a risk biomarker for metastatic canine mammary carcinoma. Veterinarski Arhiv, 90(5), 453–466. https://doi.org/10.24099/vet.arhiv.0571

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free